- Home
- TRVI vs SLP Comparison
TRVI vs SLP Comparison
Compare TRVI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- SLP
- Stock Information
- Founded
- TRVI 2011
- SLP 1996
- Country
- TRVI United States
- SLP United States
- Employees
- TRVI N/A
- SLP N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- SLP EDP Services
- Sector
- TRVI Health Care
- SLP Technology
- Exchange
- TRVI Nasdaq
- SLP Nasdaq
- Market Cap
- TRVI 725.7M
- SLP 675.9M
- IPO Year
- TRVI 2019
- SLP 1997
- Fundamental
- Price
- TRVI $6.55
- SLP $16.96
- Analyst Decision
- TRVI Strong Buy
- SLP Buy
- Analyst Count
- TRVI 9
- SLP 7
- Target Price
- TRVI $19.94
- SLP $35.40
- AVG Volume (30 Days)
- TRVI 1.6M
- SLP 612.3K
- Earning Date
- TRVI 08-07-2025
- SLP 07-14-2025
- Dividend Yield
- TRVI N/A
- SLP 0.35%
- EPS Growth
- TRVI N/A
- SLP N/A
- EPS
- TRVI N/A
- SLP 0.36
- Revenue
- TRVI N/A
- SLP $78,564,000.00
- Revenue This Year
- TRVI N/A
- SLP $27.66
- Revenue Next Year
- TRVI N/A
- SLP $6.75
- P/E Ratio
- TRVI N/A
- SLP $47.10
- Revenue Growth
- TRVI N/A
- SLP 21.49
- 52 Week Low
- TRVI $2.36
- SLP $16.72
- 52 Week High
- TRVI $7.48
- SLP $44.33
- Technical
- Relative Strength Index (RSI)
- TRVI 61.06
- SLP 28.76
- Support Level
- TRVI $5.41
- SLP $16.75
- Resistance Level
- TRVI $6.08
- SLP $18.09
- Average True Range (ATR)
- TRVI 0.32
- SLP 0.81
- MACD
- TRVI 0.09
- SLP 0.40
- Stochastic Oscillator
- TRVI 96.20
- SLP 10.76
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.